Verve Therapeutics revenue was $32.33M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $13.1M, up 90.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, VERV annual revenue was $32.3M, with 175% growth year-over-year.
VERV past revenue growth
How has VERV's revenue growth performed historically?
Verve Therapeutics (NASDAQ: VERV) reported Q4 2024 revenue of $13.08 million up 154.28% year over year. In the same quarter last year, Verve Therapeutics's revenue was $5.14 million.
What was Verve Therapeutics's revenue in 2024?
Verve Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $32.33 million, a 174.98% increase year over year.
How much does Verve Therapeutics make in a day?
Based on Verve Therapeutics annual revenue for the past five years, VERV makes an average of $25,222.47 per day.
What was Verve Therapeutics's annual revenue growth in the past year?
As of Q1 2025, Verve Therapeutics's revenue has grown 174.98% year over year. This is 246.45 percentage points lower than the US Biotechnology industry revenue growth rate of 421.43%. Verve Therapeutics's revenue in the past year totaled $32.33 million.
How much does Verve Therapeutics make in a year?
Verve Therapeutics's revenue by year for the past five years is:
Verve Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $32.33 million, a 174.98% increase year over year.
Verve Therapeutics's annual revenue for Dec 31, 2023 was $11.76 million, a 505.77% increase from 2022.
Verve Therapeutics's annual revenue for 2022 was $1.94 million, a Infinity% increase from 2021.
Verve Therapeutics's annual revenue for 2021 was $0.00, a N/A decrease from 2020.
Verve Therapeutics's annual revenue for 2020 was $0.00, a N/A decrease from 2019.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.